Stay updated on ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, with two locations now included, replacing the previous version v2.9.7.
    Difference
    0.5%
    Check dated 2024-07-23T14:35:57.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T07:59:29.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T14:01:07.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T09:59:42.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:47:22.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : ABX196 IM injection of 0.1, 0.2, and 0.4 µg of ABX196 Drug : ABX196 ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).' This change represents an update in the drug information and study design details for the clinical trial involving ABX196 in combination with Nivolumab for patients with Hepatocellular Carcinoma.
    Difference
    19%
    Check dated 2024-06-25T08:24:16.000Z thumbnail image

Stay in the know with updates to ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.